vs
Alkermes plc.（ALKS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$384.5M vs $207.3M），Alkermes plc.净利率更高（12.8% vs -62.0%，领先74.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ALKS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $207.3M |
| 净利润 | $49.3M | $-128.6M |
| 毛利率 | 88.0% | — |
| 营业利润率 | 15.1% | -54.7% |
| 净利率 | 12.8% | -62.0% |
| 营收同比 | -10.6% | 25.9% |
| 净利润同比 | -66.3% | 3.5% |
| 每股收益（稀释后） | $0.29 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $384.5M | $207.3M | ||
| Q3 25 | $394.2M | $159.9M | ||
| Q2 25 | $390.7M | $166.5M | ||
| Q1 25 | $306.5M | $139.3M | ||
| Q4 24 | $430.0M | $164.6M | ||
| Q3 24 | $378.1M | $139.5M | ||
| Q2 24 | $399.1M | $147.0M | ||
| Q1 24 | $350.4M | $108.8M |
| Q4 25 | $49.3M | $-128.6M | ||
| Q3 25 | $82.8M | $-180.4M | ||
| Q2 25 | $87.1M | $-115.0M | ||
| Q1 25 | $22.5M | $-151.1M | ||
| Q4 24 | $146.5M | $-133.2M | ||
| Q3 24 | $92.4M | $-133.5M | ||
| Q2 24 | $91.4M | $-131.6M | ||
| Q1 24 | $36.8M | $-170.7M |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | -54.7% | ||
| Q3 25 | 22.6% | -106.9% | ||
| Q2 25 | 23.8% | -64.8% | ||
| Q1 25 | 4.5% | -102.6% | ||
| Q4 24 | 37.8% | -74.3% | ||
| Q3 24 | 27.7% | -94.6% | ||
| Q2 24 | 27.5% | -79.1% | ||
| Q1 24 | 12.4% | -151.9% |
| Q4 25 | 12.8% | -62.0% | ||
| Q3 25 | 21.0% | -112.8% | ||
| Q2 25 | 22.3% | -69.0% | ||
| Q1 25 | 7.3% | -108.5% | ||
| Q4 24 | 34.1% | -80.9% | ||
| Q3 24 | 24.4% | -95.7% | ||
| Q2 24 | 22.9% | -89.5% | ||
| Q1 24 | 10.5% | -156.8% |
| Q4 25 | $0.29 | $-1.28 | ||
| Q3 25 | $0.49 | $-1.81 | ||
| Q2 25 | $0.52 | $-1.17 | ||
| Q1 25 | $0.13 | $-1.57 | ||
| Q4 24 | $0.88 | $-1.34 | ||
| Q3 24 | $0.55 | $-1.40 | ||
| Q2 24 | $0.53 | $-1.52 | ||
| Q1 24 | $0.21 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $-80.0M |
| 总资产 | $2.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $388.6M | $421.0M | ||
| Q3 25 | $616.4M | $202.5M | ||
| Q2 25 | $521.2M | $176.3M | ||
| Q1 25 | $399.8M | $127.1M | ||
| Q4 24 | $291.1M | $174.0M | ||
| Q3 24 | $396.3M | $150.6M | ||
| Q2 24 | $535.1M | $480.7M | ||
| Q1 24 | $420.8M | $112.3M |
| Q4 25 | $1.8B | $-80.0M | ||
| Q3 25 | $1.7B | $9.2M | ||
| Q2 25 | $1.6B | $151.3M | ||
| Q1 25 | $1.5B | $144.2M | ||
| Q4 24 | $1.5B | $255.0M | ||
| Q3 24 | $1.3B | $346.8M | ||
| Q2 24 | $1.3B | $432.4M | ||
| Q1 24 | $1.3B | $140.3M |
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.3B | $1.2B | ||
| Q2 25 | $2.3B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.2B | $1.6B | ||
| Q1 24 | $2.1B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 44.2% | -48.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.45× | — |
| 过去12个月自由现金流最近4个季度 | $480.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $170.1M | $-99.8M | ||
| Q3 25 | $101.7M | $-91.4M | ||
| Q2 25 | $150.2M | $-108.3M | ||
| Q1 25 | $98.8M | $-166.5M | ||
| Q4 24 | $190.4M | $-79.3M | ||
| Q3 24 | $81.6M | $-67.0M | ||
| Q2 24 | $146.0M | $-77.0M | ||
| Q1 24 | $21.1M | $-190.7M |
| Q4 25 | $170.0M | $-100.8M | ||
| Q3 25 | $84.4M | $-92.7M | ||
| Q2 25 | $137.2M | $-110.7M | ||
| Q1 25 | $88.7M | $-167.8M | ||
| Q4 24 | $180.6M | $-79.5M | ||
| Q3 24 | $73.3M | $-68.6M | ||
| Q2 24 | $138.9M | $-79.0M | ||
| Q1 24 | $12.8M | $-193.9M |
| Q4 25 | 44.2% | -48.6% | ||
| Q3 25 | 21.4% | -58.0% | ||
| Q2 25 | 35.1% | -66.5% | ||
| Q1 25 | 28.9% | -120.5% | ||
| Q4 24 | 42.0% | -48.3% | ||
| Q3 24 | 19.4% | -49.2% | ||
| Q2 24 | 34.8% | -53.7% | ||
| Q1 24 | 3.6% | -178.2% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 4.4% | 0.8% | ||
| Q2 25 | 3.3% | 1.5% | ||
| Q1 25 | 3.3% | 1.0% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 1.8% | 1.4% | ||
| Q1 24 | 2.4% | 3.0% |
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
